Imatinib: a breakthrough of targeted therapy in cancer
N Iqbal, N Iqbal - Chemotherapy research and practice, 2014 - Wiley Online Library
Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …
Imatinib as a paradigm of targeted therapies
BJ Druker - Advances in cancer research, 2004 - books.google.com
Imatinib as a paradigm of targeted therapies Page 10 Imatinib as a Paradigm of Targeted
Therapies Brian J. Druker Howard Hughes Medical Institute, Cancer Institute, Oregon Health …
Therapies Brian J. Druker Howard Hughes Medical Institute, Cancer Institute, Oregon Health …
Imatinib mesylate
CF Waller - Small molecules in hematology, 2018 - Springer
Abstract Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents …
Pharmacology of imatinib (STI571)
E Buchdunger, T O'Reilley, J Wood - European journal of cancer, 2002 - Elsevier
Deregulation of protein kinase activity has been shown to play a central role in the
pathogenesis of human cancer. The molecular pathogenesis of chronic myelogenous …
pathogenesis of human cancer. The molecular pathogenesis of chronic myelogenous …
Clinical pharmacokinetics of imatinib
B Peng, P Lloyd, H Schran - Clinical pharmacokinetics, 2005 - Springer
Imatinib is a potent and selective inhibitor of the protein tyrosine kinase Bcr-Abl, platelet-
derived growth factor receptors (PDGFRα and PDGFRβ) and KIT. Imatinib is approved for …
derived growth factor receptors (PDGFRα and PDGFRβ) and KIT. Imatinib is approved for …
Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours
H Joensuu, S Dimitrijevic - Annals of medicine, 2001 - Taylor & Francis
Imatinib mesylate, also known as ST1571 or CGP57148, is a competitive inhibitor of a few
tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor …
tyrosine kinases, including BCR-ABL, ABL, KIT, and the platelet-derived growth factor …
Indications for imatinib mesylate therapy and clinical management
F Guilhot - The oncologist, 2004 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the mechanism of action (ie, the molecular targets) of the anticancer drug imatinib …
Describe the mechanism of action (ie, the molecular targets) of the anticancer drug imatinib …
Imatinib mesylate (Gleevec/Glivec) a molecular‐targeted therapy for chronic myeloid leukaemia and other malignancies
E Nadal, E Olavarria - International journal of clinical practice, 2004 - Wiley Online Library
Summary Imatinib mesylate (Gleevec®/Glivec®, Novartis, Basel, Switzerland), formerly
called STI571, is a specific and potent inhibitor of the BCR‐ABL tyrosine kinase, the …
called STI571, is a specific and potent inhibitor of the BCR‐ABL tyrosine kinase, the …
Resistance to imatinib (Glivec): update on clinical mechanisms
E Weisberg, JD Griffin - Drug Resistance Updates, 2003 - Elsevier
Imatinib mesylate, an orally administered 2-phenylaminopyrimidine derivative that inhibits
BCR/ABL tyrosine kinase activity, has shown great promise in the treatment of chronic …
BCR/ABL tyrosine kinase activity, has shown great promise in the treatment of chronic …
Imatinib mesylate—a new oral targeted therapy
DG Savage, KH Antman - New England Journal of Medicine, 2002 - Mass Medical Soc
This review discusses the development and uses of imatinib mesylate, a protein tyrosine
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …